207 related articles for article (PubMed ID: 32256114)
21. Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.
Chiang PJ; Xu T; Cha TL; Tsai YT; Liu SY; Wu ST; Meng E; Tsao CW; Kao CC; Chen CL; Sun GH; Yu DS; Chang SY; Yang MH
Biology (Basel); 2021 Jul; 10(7):. PubMed ID: 34356529
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C
Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Kloten V; Lampignano R; Krahn T; Schlange T
Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
[TBL] [Abstract][Full Text] [Related]
25. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
[TBL] [Abstract][Full Text] [Related]
27. In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.
Jin D; Qian L; Xia J; Zhang R; Yang G; Zhang L; Xue W; Cao M; Dong L; Chen H
Med Oncol; 2023 Mar; 40(4):113. PubMed ID: 36884136
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
[TBL] [Abstract][Full Text] [Related]
29. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.
Papadaki MA; Sotiriou AI; Vasilopoulou C; Filika M; Aggouraki D; Tsoulfas PG; Apostolopoulou CA; Rounis K; Mavroudis D; Agelaki S
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545559
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
[TBL] [Abstract][Full Text] [Related]
31. Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I-III Non-small Cell Lung Cancer Patients.
Dong J; Zhu D; Tang X; Qiu X; Lu D; Li B; Lin D; Zhou Q
Front Oncol; 2019; 9():1139. PubMed ID: 31737568
[No Abstract] [Full Text] [Related]
32. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.
Winograd P; Hou S; Court CM; Lee YT; Chen PJ; Zhu Y; Sadeghi S; Finn RS; Teng PC; Wang JJ; Zhang Z; Liu H; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
Hepatol Commun; 2020 Oct; 4(10):1527-1540. PubMed ID: 33024921
[TBL] [Abstract][Full Text] [Related]
34. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.
Yue C; Jiang Y; Li P; Wang Y; Xue J; Li N; Li D; Wang R; Dang Y; Hu Z; Yang Y; Xu J
Oncoimmunology; 2018; 7(7):e1438111. PubMed ID: 29900038
[No Abstract] [Full Text] [Related]
35. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653
[TBL] [Abstract][Full Text] [Related]
36. Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
Acheampong E; Spencer I; Lin W; Ziman M; Millward M; Gray E
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31262041
[TBL] [Abstract][Full Text] [Related]
37. Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.
Matsuoka H; Araya T; Kita T; Terada N; Yamamura K; Nishikawa S; Tambo Y; Sone T; Kimura H; Ooi A; Kasashima S; Kawashima A; Kasahara K
J Cancer; 2021; 12(15):4478-4487. PubMed ID: 34149911
[No Abstract] [Full Text] [Related]
38. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
39. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Tomita Y; Oronsky B; Abrouk N; Cabrales P; Reid TR; Lee MJ; Yuno A; Baker J; Lee S; Trepel JB
Transl Lung Cancer Res; 2021 Jan; 10(1):274-278. PubMed ID: 33569311
[TBL] [Abstract][Full Text] [Related]
40. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
